


TITLE PAGE

Residue Levels of Imidacloprid and Imidacloprid Metabolites in Honeybees Orally
Dosed with Imidacloprid in Standardized Toxicity Tests (EPPO 170)

AUTHOR



TESTING FACILITY

BAYER AG
Crop Protection-Development
Institute For Environmental Biology
D-51368 Leverkusen-Bayerwerk

GLP STUDY NUMBER

E 370 1725 05

REPORT NUMBER

SXR/Am 013

TOTAL NUMBER OF PAGES

22

STUDY COMPLETION DATE:

30 September 1999




SXR/Am 013 / MO-99-015992

Dit document is geen eigendom van het Ctgb en wordt beschikbaar gemaakt op grond van een wettelijke verplichting tot openbaarmaking. Op dit document kunnen rechten van derden rusten, waaronder intellectuele eigendomsrechten/ of auteursrechten. Voorts kan dit document onder een regeling van auteursrechtelijke bescherming vallen. Publicatie, verspreiding, vermenigvuldiging, commerciële exploitatie en gebruik van dit document kan derhalve verboden zijn en een inbreuk opleveren op de rechten van de rechthebbende.

This document is not the property of the Ctgb and only provided based on mandatory freedom of information requirements. The document may be subject to rights such as intellectual property and copy rights of third parties. Furthermore, this document may fall under regulatory data protection and any commercial exploitation and use of this document or its contents without the permission of the owner of this document may therefore be prohibited and violate the rights of its owner.

STATEMENT OF COMPLIANCE


This study was conducted in compliance with the Principles of Good Laboratory Practice (Chemicals Law (ChemG) of July 25, 1994, Annex 1 and OECD Principles of Good Laboratory Practice (GLP) of November 26, 1997 [C(97) 186/Final]).



Dit document is geen eigendom van de Staat.
Op dit document kunnen auteursrechten van toepassing zijn.
Voorts kan het gebruik van dit document beperkt zijn.
Publicatie, verspreiding, vermenigvuldiging, kopiëren, verspreiden of anderszins openbaar maken van dit document kan strafbaar zijn.
This document is not the property of the Ctgb and is not to be distributed outside the Ctgb.
The document may be subject to rights of copyright and/or other intellectual property rights.
Furthermore, this document may be subject to other laws, regulations and/or administrative provisions.
Consequently, any publication, distribution, reproduction and/or public use of this document may be prohibited without the permission of the owner of this document.

Verplichting tot openbaarmaking.
Zonder de toestemming van de rechthebbende.
its contents

CERTIFICATION OF AUTHENTICITY



Study Director

30/9/99

Title

Date

Responsible Analyst
Biological Samples

30.9.99

Title

Date

Head of Institute for
Environmental Biology

30.9.99

Title

Date

INQUIRIES

Inquiries should be directed to:

BAYER AG
Crop Protection - Development
Institute for Environmental Biology
D-51368 Leverkusen - Bayerwerk, FRG



Dit document is geen eigendom van... Op dit document kunnen rechten... Voorts kan... Publicatie, verspreiding, vermenigvuldiging, com... rechthebbende van dit document kan a... document is not the property of the Ctgb and only provided based on mandatory freedom of information requirements. Consequently, any publication, distribution, reproduction and/or publishing and any commercial exploitation and use of this document or its contents without the permission of the owner of this document may therefore be prohibited and violate the rights of its owner.

TABLE OF CONTENTS

	Page No.
TITLE PAGE	1
STATEMENT OF COMPLIANCE.....	2
CERTIFICATION OF AUTHENTICITY.....	3
TABLE OF CONTENTS.....	4
1.0 SUMMARY	5
2.0 INTRODUCTION	6
3.0 EXPERIMENTAL.....	6
3.1 Test Substance.....	6
3.2 Reference Substance	6
3.3 Execution of the Test.....	6
3.4 Origin of Honeybees	7
3.5 Test Cages and Labelling Procedure.....	7
3.6 Food Provided to the Honeybees During the Test.....	7
3.7 Study Procedure.....	7
3.7 Evaluation.....	7
3.8 Sample Processing and Residue Analysis.....	7
4.0 FILING 7	
5.0 RESULTS AND DISCUSSION.....	8
5.1 Biological Observations on Foraging Honeybees.....	8
5.2 Analytical Findings.....	8
TABLES 9	
Table 1: Time to Death and Symptoms Observed During the LD50 Study.....	9
Table 2: Residue Levels of Imidacloprid and Toxicologically Relevant Metabolites in Honeybees Orally Dosed with Imidacloprid.....	10
APPENDICES.....	11
Appendix I: Analytical Report for Bee Samples.....	11
Appendix II: Copy of the GLP Certificate.....	20
Appendix III: Quality Assurance Statement.....	22

Dit document is geen eigendom van het Ctgb en wordt beschikbaar gemaakt op grond van een wettelijke verplichting tot openbaarmaking.
 Op dit document kunnen rechten van auteursrechten, waaronder intellectuele eigendomsrechten en/of auteursrechten.
 Voor het gebruik van dit document onder een regeling omtrent goederenrechten, zoals de Wet op de Auteursrechten, is het niet toegestaan.
 Het gebruik van dit document kan commerciële exploitatie verboden zijn en een inbreuk opleveren van de rechten van de rechthebbende.
 This document is not the property of the Ctgb and is only provided based on mandatory freedom of information requirements.
 The document may be subject to rights such as intellectual property and copy rights of third parties.
 Consequently, any publication, distribution, reproduction and use of this document may therefore be prohibited and violate the rights of its owner.

1.0 SUMMARY

Report: [REDACTED] 1999): Residue Levels of Imidacloprid and Imidacloprid Metabolites in Honeybees Orally Dosed with Imidacloprid in Standardized Toxicity Tests (EPPO 170)

Bayer AG, unpublished report No: SXR/Am 013; 1999/09/30.

(tab 1 report data from IBACON study 6400036; app I contains data from MR study -575/99).

Guidelines: Internal Testing Method (deviations: not applicable)

GLP: yes (certified laboratory)

Material and methods: test substance specification: imidacloprid techn., batch no. M00680, purity 99.4%. Adult honeybees were orally dosed with either 0.0001, 0.0008, 0.0015, 0.0031, 0.006, 0.012, 0.023 or 0.041 µg/honeybee imidacloprid techn.. Honeybees which died during the study were removed from the test boxes at each evaluation and stored at -20°C. At study termination, alive honeybees were killed by CO₂ asphyxiation and retained also at -20°C till residue analysis. After shipping the honeybee samples to Bayer AG, they were analysed for residues of imidacloprid and toxicologically relevant metabolites, i.e. olefin- and hydroxy-imidacloprid.

Dates of biological work: July 6 – 10, 1999 (IBACON study 6400036).

Dates of analysis of biological samples: September 15 – 17, 1999.

Findings: Residues in honeybees orally dosed with imidacloprid techn.:

Dose Applied [ng/bee]	Time to Death [h]	Sample weight [g]	Hydroxy-NTN [mg/kg]	Olefin-NTN [mg/kg]	Imidacloprid [mg/kg]
0.1	-- **	3.8	n.d.	n.d.	n.d.
0.8	-- **	4.1	n.d.	n.d.	n.d.
1.5	-- **	3.7	n.d.	n.d.	n.d.
3.1	4	0.3	n.d.	n.d.	< LOQ
	24	0.6	< LOQ	n.d.	n.d.
	-- **	2.7	< LOQ	n.d.	n.d.
6.0	24	0.7	< LOQ	n.d.	n.d.
	-- **	2.7	< LOQ	n.d.	n.d.
12.0	24	0.5	< LOQ	n.d.	n.d.
	-- **	2.8	0.006	n.d.	n.d.
22.9	24/48	0.4	0.010	< LOQ	< LOQ
	-- **	3.3	0.010	< LOQ	n.d.
40.9	1/1 15	0.2	n.d.	n.d.	< LOQ
	24	0.6	0.006	n.d.	0.017
	48/72	0.7	0.040	0.010	< LOQ
	-- **	1.8	0.006	< LOQ	n.d.

* Limit of quantitation: 0.005 mg/kg (imidacloprid & hydroxy-metabolite, 0.01 mg/kg (olefin-metabolite); n.d. = below limit of detection (0.0015 mg/kg and 0.003 mg/kg, respectively)

** Honeybees were asphyxiated by CO₂ at study termination.

Observations: Oral doses of 1.5 ng/bee or less had no observable adverse effects on honeybees and no residues of imidacloprid or the olefin- and hydroxy-metabolite could be detected in those bees. All other doses caused adverse effects and residues of imidacloprid or the olefin- and hydroxymetabolite could be detected in the respective honeybee samples. In most cases, the highest residue level was found for the hydroxy-metabolite which may be a suitable indicator for a significant exposure of honeybees to imidacloprid.

2.0 INTRODUCTION

The objective of this study was to consider whether or not imidacloprid-related bee incidents could be identified by a characteristic residue pattern in honeybees which had been exposed to harmful imidacloprid doses.

Honeybees were orally dosed with imidacloprid techn. in an acute toxicity test according to EPPO guideline no. 170 performed by a contract research facility (IBACON, Roßdorf). The honeybees from this test were asphyxiated by CO₂ at test termination at the latest and retained at -20°C till residue analysis. The residue findings on these honeybees are reported here.

3.0 EXPERIMENTAL

3.1 Test Substance

Test substance:	imidacloprid techn.
Active ingredient(s):	imidacloprid (NTN 33893)
Chemical name(s) of ai(s):	2-Imidazolidinimine, 1-[(6-chloro-3-pyridinyl)methyl]-N-nitro-
CAS number of ai(s):	138261-41-3
Indikation:	insecticidal seed dressing
Formulation/batch number:	M00680
Date of certificate:	March 30, 1998
Purity (acc. to analysis):	99.4%
Analytical method:	HPLC
Date of analysis:	March 13, 1998
Expiry date:	March 2000
Physical appearance:	colourless crystals
Specific density:	not applicable
Storage conditions:	room temperature
Doses applied in the LD50 study:	0.1, 0.8, 1.5, 3.1, 6, 12.2, 22.9 and 40.9 ng/honeybee.
Safety precaution:	Routine hygienic precautions

3.2 Reference Substance

For this type of study, a reference compound is not applicable.

3.3 Execution of the Test

The acute LD50 study was performed between 6 July and 10 July 1999 by the contract research institute IBACON GmbH, Roßdorf, Germany (IBACON report no. 6400036). The honeybees from this study were shipped to the Bayer AG on 20. August 1999.

Sponsor:	BAYER AG GB Plant Protection Marketing - Seed Treatment D-40789 Monheim
----------	--

Study Director:	
Responsible Analyst:	
Study Technicians:	

Quality Assurance:

Laboratory Study Number:

SXR/Am 013

3.4 Origin of Honeybees

Honeybees (*Apis mellifera mellifera* L.) of different age were sampled from the flight board of disease-free and queen-right bee hives managed by IBACON GmbH, Roßdorf, Germany.

3.5 Test Cages and Labelling Procedure

The honeybees were caged in groups of 10 individuals each in stainless steel chambers (10 x 8.5cm and 5.5 cm high) with the front side consisting of a removable glass plate. The test chambers were perforated with 98 ventilation holes (d = 1 mm) and were lined with filter paper. For each dosage 3 replicates with 10 honeybees each were prepared. The test chambers were uniquely identified with the study number, application date, treatment, test concentration and the replicate number.

3.6 Food Provided to the Honeybees During the Test

After oral dosing, honeybees received a commercial ready-to-use syrup (Aplinvert: 30% saccharose, 31% glucose, 39% fructose) *ad libitum* till test termination.

3.7 Study Procedure

After collecting honeybees were allocated impartially to the test chambers of the different dose groups and starved for 70 minutes. Some 20 mg of a commercial ready-to-use syrup per honeybee was mixed with 8 different amounts of imidacloprid and offered in syringes which were weight before and after the dosing phase (dosing phase was restricted to 3 hours). During the dosing and the subsequent 96 hr observation phase honeybees were maintained in incubators at 29°C and 50-70% RH in darkness (except during evaluations).

3.7 Evaluation

Two parameters were assessed during the study: mortality and behavioural abnormalities such as vomiting, apathy, intensive cleaning, exaggerated and/or dis-coordinated movements. The number of dead and behaviourally impacted bees were recorded on the exposure day 1, 2 and 4 hr after honeybees had ingested the syrup. Further evaluations were made 24, 48, 72 and 96 hr later. After the final evaluation, all survivors were asphyxiated by CO₂ and stored at -20°C. All bees which died before study termination were removed from the cages and also stored in a freezer.

3.8 Sample Processing and Residue Analysis

Honeybee samples were shipped to the Agricultural Centre of the Bayer AG in Monheim on 20 August 1999. During shipment they were retained on dry ice at -20°C. After arrival, they were transferred into a freezer and retained at -20°C till residue analysis. Sample processing and analytical methods are described in detail in appendix I.

4.0 FILING

All raw data, the study protocol and the original of the report are filed in the Central GLP archive of PF/E, Crop Protection Center 40789 Monheim, FRG. Reserve samples of the test substance are stored in the pertinent archive of that test facility which provided or certified the test substance.

5.0 RESULTS AND DISCUSSION

5.1 *Biological Observations on Foraging Honeybees*

Oral doses up to 1.5 ng/bee had no observable adverse effect on the honeybees (table 1). At doses between 3.1 and 12.2 ng/bee the number of affected bees and effect duration increased in a dose-dependent manner. Higher doses (22.9 and 40.9 ng/bee) did not further increase the number of affected bees. This may be attributed by an impact on the trophallactic behavior (= social feeding) of the honeybees.

5.2 *Analytical Findings*

No residues of imidacloprid or the olefin- and hydroxy-metabolite could be detected in honeybees fed with imidacloprid doses which had no observable effects on the bees. At all doses which caused effects residues above the limit of detection were found for either the parent compound or the olefin- and hydroxy-metabolite. The residue levels found corresponded well with the applied imidacloprid doses. From the time to appearance of the respective metabolite it appears that imidacloprid is readily degraded in honeybees. In most cases, the highest residue level was found for the hydroxy-metabolite which may be a suitable indicator for a significant exposure of honeybees to imidacloprid.

Dit document is geen eigendom van het Ctgb en wordt beschikbaar gemaakt op grond van de wettelijke verplichting tot openbaarmaking.

Op dit document kunnen rechten van derden rusten, waaronder intellectuele eigendomsrechten en/of auteursrechten.

Voorts kan dit document onder een regeling omtrent gegevensbescherming vallen.

Publicatie, verspreiding, vermenigvuldiging, commerciële exploitatie en gebruik van dit document zijn een inbreuk op het auteursrecht van deze rechthebbende van dit document kan derhalve verboden zijn en een inbreuk opleveren op het auteursrecht van deze rechthebbende van dit document.

This document is not the property of the Ctgb and only provided based on mandatory freedom of information requirements.

The document may be subject to rights such as intellectual property and copy rights of third parties.

Furthermore, this document may fall under a regulatory data protection and use of this document or its contents without the permission of the owner of this document may therefore be prohibited and violate the rights of its owner.

TABLES

Table 1: Time to Death and Symptoms Observed During the LD50 Study.
 These data originate from an oral LD50 study (IBACON 6400036).

Dose Applied	Time to Death [time to death in h / no. of dead bees]	Symptoms Observed [type of symptoms / no of affected bees]
Control	2 h / 1	apathy (2-4 h) 1
	24 h / 1	
	48 h / 1	
0.1	-- / 0	--
0.8	-- / 0	--
1.5	4 h / 1	--
3.1	4 h / 3	apathy (2-4h) 3
	24 h / 7	exaggerated (4 h) 4 discoordination(2-4 h) 2
6.0	4 h / 2	apathy (2-4h) 12
	24 h / 8	discoordination(2-4h) 9
12.2	1 h / 7	apathy (2-24h) 29
	24 h / 6	exaggerated (4 h) 19
	48 h / 2	discoordination (2-4 h) 19
22.9	1 h / 1	apathy (1-24h) 28
	24 h / 3	exaggerated (1-4 h) 13
	48 h / 1	discoordination(1-24 h) 14
40.9	1 h / 2	apathy (1-24h) 28
	24 h / 6	exaggerated (1 -48h) 8
	48 h / 7	discoordination(1-24 h) 18
	72 h / 1	

Dit document is geen eigendom van het Ctgb en wordt beschikbaar gemaakt op grond van een wettelijke verplichting tot openbaarmaking. Op dit document kunnen rechten van derden rusten, waaronder intellectuele eigendomsrechten en/of auteursrechten. Voorts kan dit document onder een reguliere gebruik van dit document of de inhoud hiervan zonder de toestemming van de rechthebbende van dit document kan derhalve verboden zijn en een inbreuk opleveren van de rechten van deze rechthebbende.

This document is not the property of the Ctgb and only provided based on mandatory freedom of information requirements. The document may be subject to rights such as intellectual property and copy rights of third parties. Furthermore, this document may fall under a regulatory data protection regime. Consequently, any publication, distribution, reproduction and/or publishing may be prohibited and violate the rights of its owner.

Table 2: Residue Levels of Imidacloprid and Toxicologically Relevant Metabolites in Honeybees Orally Dosed with Imidacloprid.

The honeybee samples originate from an acute LD50 study (IBACON 6400036).

Dose Applied [ng/bee]	Time to Death [h]	Sample weight [g]	Hydroxy-NTN [mg/kg]	Olefin-NTN [mg/kg]	Imidacloprid [mg/kg]
0.1	96	3.8	n.d.	n.d.	n.d.
0.8	96	4.1	n.d.	n.d.	n.d.
1.5	96	3.7	n.d.	n.d.	n.d.
3.1	4	0.3	n.d.	n.d.	< LOQ
	24	0.6	< LOQ	n.d.	n.d.
	96	2.7	< LOQ	n.d.	n.d.
6.0	24	0.7	< LOQ	n.d.	n.d.
	96	2.7	< LOQ	n.d.	n.d.
12.2	24	0.5	< LOQ	n.d.	n.d.
	96	2.8	0.006	n.d.	n.d.
22.9	24/48	0.4	0.010	< LOQ	< LOQ
	96	3.3	0.010	< LOQ	n.d.
40.9	1/1.25	0.2	n.d.	n.d.	< LOQ
	24	0.6	0.006	n.d.	0.017
	48/72	0.7	0.040	0.010	< LOQ
	96	1.8	0.006	< LOQ	n.d.

* Limit of quantitation: 0.005 mg/kg (imidacloprid & hydroxy-metabolite, 0.01 mg/kg (olefin-metabolite);
n.d. = below limit of detection (0.0015 mg/kg and 0.003 mg/kg respectively)

Dit document is geen eigendom van het Ctgb en wordt beschikbaar gemaakt op grond van een wettelijke verplichting tot openbaarmaking.
 Op dit document kunnen rechten van derden rusten, waaronder intellectuele eigendomsrechten en/of auteursrechten.
 Voorts kan dit document onder een regeling omtrent gegevensbescherming vallen.
 Publicatie, verspreiding, vermenigvuldiging, commerciële exploitatie en gebruik van dit document of de inhoud hiervan zonder de toestemming van de rechthebbende van dit document is strafbaar.
 This document is not the property of the Ctgb and only provided based on mandatory freedom of information requirements.
 The document may be subject to rights of third parties.
 Furthermore, any publication, distribution, reproduction and/or publishing and any commercial exploitation and use of this document or its contents without the permission of the owner of this document is prohibited and violate the rights of its owner.

APPENDICES

APPENDIX I: Analytical Report for Bee Samples.

Bayer AG
Crop Protection Development
Institute for Metabolism Research
and Residue Analysis
D-51368 Leverkusen

September 29, 1999
Report No.: MR-575/99

STUDY TITLE

**Residue Levels of Imidacloprid and Imidacloprid Metabolites in Honeybees Orally
Dosed with Imidacloprid in Standardized Toxicity Tests (EPPO 170)**

Author

[Redacted]

Testing Facility

Bayer AG
PF-E/MR, Building 6610
51368 Leverkusen, Germany

Study Completion Date

September 29, 1999

Study Number

E 370 1725 - 5

TABLE OF CONTENT

	Page No.
STUDY TITLE	32
TABLE OF CONTENT	33
1 INTRODUCTION	34
2 TIME SCHEDULE	34
3 RESULTS OF BEE MATERIAL SAMPLES :	34
3.1 Bee Samples:	36
4 EXPERIMENTAL	37
4.1 Reference Substances	37
4.2 Residue Analytical Methodology	38
4.2.1 Extraction and Sample Clean-up	38
4.2.2 ChemElut [®] Column Clean-up	38
4.2.3 Silica Gel Column Clean-up	39
4.3 HPLC-MS/MS determination of Imidacloprid and Metabolites	40
4.3.1 Measuring equipment and HPLC conditions:	40
4.3.2 MS/MS-Detection	41

Dit document is geen eigendom van het Ctgb en wordt beschikbaar gemaakt op grond van een wettelijke verplichting tot openbaarmaking.
 Op dit document kunnen rechten van derden rusten, waaronder intellectuele eigendomsrechten en/of auteursrechten.
 Voorts kan dit document onder een regeling omtrent gegevensbescherming vallen.
 Publicatie, verspreiding, vermenigvuldiging, commerciële exploitatie en gebruik van dit document of de inhoud hiervan zonder de toestemming van de rechthebbende van dit document kan derhalve verboden zijn en een inbreuk opleveren van de rechten van deze rechthebbende.
 This document is not the property of the Ctgb and only provided based on mandatory freedom of information requirements.
 The document may be subject to rights such as intellectual property and copy rights of third parties.
 Furthermore, this document may fall under a regulatory data protection regime.
 Consequently, any publication, distribution, reproduction and/or publishing and any commercial exploitation and use of this document or its contents without the permission of the owner of this document may therefore be prohibited and violate the rights of its owner.

1 INTRODUCTION

Honeybee samples from an acute LD50 study (IBACON 6400036) were analysed for residues of imidacloprid and its olefin- and hydroxy metabolites. The results are tabulated in the table below. Extraction, sample clean up and determination of imidacloprid, hydroxy- and olefin-metabolite by HPLC-MS/MS were performed according to method 00537/E001 (MR-568/99). The limit of quantitation was 0.005 mg/kg for imidacloprid and the hydroxy-metabolite and 0.01 mg/kg for the olefin-metabolite. The limit of detection was 0.0015 mg/kg for imidacloprid and the hydroxy-metabolite and 0.003 mg/kg for the olefin-metabolite.

2 TIME SCHEDULE

The experimental work was performed during the following time period:

Signature of Study Protocol: September 15, 1999
 Start of Experimental Phase: September 15, 1999
 End of Experimental Phase: September 17, 1999
 Completion of Report: September 29, 1999

3 RESULTS FOR BEE MATERIAL SAMPLES :

3.1 Bee Samples:

Dose Applied [ng/bee]	Time to Death [h]	Sample weight [g]	Hydroxy-NTN [mg/kg]	Olefin-NTN [mg/kg]	Imidacloprid [mg/kg]
0.1	96	3.8	n.d.	n.d.	n.d.
0.3	96	4.0	n.d.	n.d.	n.d.
1.0	96	3.7	n.d.	n.d.	n.d.
3.1	4	0.3	n.d.	n.d.	< LOQ
	24	0.6	< LOQ	n.d.	n.d.
	96	2.7	< LOQ	n.d.	n.d.
6.0	24	0.7	< LOQ	n.d.	n.d.
	96	2.7	< LOQ	n.d.	n.d.
12.2	24	0.5	< LOQ	n.d.	n.d.
	96	2.8	0.006	n.d.	n.d.

Limit of quantitation: 0.005 mg/kg for Imidacloprid and Hydroxy-Metabolite, 0.01 mg/kg for the Olefin-Metabolite; < 0.005 and < 0.010 = Residues below the limit of quantitation.

Limit of detection: 0.0015 mg/kg for Imidacloprid and Hydroxy-Metabolite, 0.003 mg/kg for the Olefin-Metabolite; n.d.: Residues below the limit of detection.

Dose Applied [ng/bee]	Time to Death [h]	Sample weight [g]	Hydroxy-NTN [mg/kg]	Olefin-NTN [mg/kg]	Imidacloprid [mg/kg]
22.9	24/48	0.4	0.010	< LOQ	< LOQ
	96	3.3	0.010	< LOQ	n.d.
40.9	1/1.15	0.2	n.d.	n.d.	< LOQ
	24	0.6	0.006	n.d.	0.017
	48/72	0.7	0.040	0.010	< LOQ
	96	1.8	0.006	< LOQ	n.d.

Limit of quantitation: 0.005 mg/kg for Imidacloprid and Hydroxy-Metabolite, 0.01 mg/kg for the Olefin-Metabolite; < 0.005 and <0.010 = Residues below the limit of quantitation.

Limit of detection: 0.0015 mg/kg for Imidacloprid and Hydroxy-Metabolite, 0.003 mg/kg for the Olefin-Metabolite; n.d.: Residues below the limit of detection.

Dit document is geen eigendom van het Ctgb en wordt beschikbaar gemaakt op grond van een wettelijke verplichting tot openbaarmaking. Op dit document kunnen rechten van derden rusten, waaronder intellectuele eigendomsrechten en/of auteursrechten. Voorts kan dit document onder een regeling omtrent gegevensbescherming vallen. Het gebruik van dit document of de inhoud hiervan zonder de toestemming van de rechthebbende van dit document kan derhalve verboden zijn en een inbreuk opleveren van auteursrechten en/of andere rechten van de rechthebbende.


This document is not the property of the Ctgb and only provided based on mandatory freedom of information requirements. The document may be subject to rights such as intellectual property and copy rights of third parties. Consequently, any publication, distribution and/or publishing and any commercial exploitation and use of this document or its contents without the permission of the owner of this document may therefore be prohibited and violate the rights of its owner.

4 EXPERIMENTAL

4.1 Reference Substances

Imidacloprid


Structural formula:



Empirical formula: $C_9H_{10}ClN_5O_2$
 Molecular weight: 255.7 g/mole
 Certificate of Analysis: M00680, 03/13/98
 Certified Assay: 99.4 %
 Expiry Date: March 2000

Hydroxy-Imidacloprid (WAK 4103)


Structural formula:



Empirical formula: $C_9H_{10}ClN_5O_4$
 Molecular weight: 271.7 g/mole
 Certificate of Analysis: 930323ELB03, 06/07/95
 Certified Assay: 99.4 %
 Expiry Date: June 2000

Olefin-Imidacloprid (NTN 35884)

Structural formula:



Empirical formula: $C_9H_8ClN_5O_2$
 Molecular weight: 253.6 g/mole
 Certificate of Analysis: M00804, 07/22/98
 Certified Assay: 98 %
 Expiry Date: June 2000

4.2 Residue Analytical Methodology

4.2.1 Extraction and Sample Clean-up

1. Place e.g. 2.0 g of the sample material in a 150-ml beaker.
Add 30 ml of methanol/water (3/1, v/v) and allow the sample to soak for 30 min.
2. Blend the sample using an ultra-turrax blender (or equivalent) for approximately 1 min.
3. Vacuum filter the suspension through 2.5 g of Celite filter aid using Schwarzband filter paper supported on a Büchner funnel into a 250-ml vacuum filter flask.
4. Wash the filtered solids with a total of 30 ml of methanol/water (3/1, v/v). Press residual solvent from the solids using rubber damming. Discard the filtered solids.
5. Transfer the filtrate to a 100-ml graduated cylinder. Determine the total volume of the extracts. Mix the solution well, and transfer one half (e.g. 1.0 g sample equivalent) to a 250-ml brown glass round-bottomed flask.
6. Concentrate the aliquot to an aqueous remainder of 5 to 10 ml using a rotary evaporator with a max. bath temperature of 50 °C.

4.2.2 ChemElut[®] Column Clean-up

1. Add 5 to 10 ml water to the aqueous solution from 4.2.1 step 6 to bring the total volume of the extracts to approx. 20 ml.
2. Place the aqueous solution on the top of the ChemElut[®] CE 1020 (20 ml volume) column fitted with a disposable stainless steel needle and wait for approx. 15 minutes to achieve a uniform distribution of the liquid on the column.
3. Elute the residues from the column with 140 ml of CH₂Cl₂. Collect the eluate in a 250-ml brown glass round-bottomed flask.
4. Evaporate the eluate from step 3 to dryness using a vacuum rotary evaporator and a max. bath temperature of 40 °C.

4.2.3 Silica Gel Column Clean-up

1. Dissolve the residues from 4.2.2 step 4 in 2 ml of toluene/ethyl acetate (85/15, v/v).
2. Apply the organic solution from step 1 onto a 0.5 g (3 ml) silica gel (SiOH) column (e.g. Varian).
3. Allow the solution to pass through the column at a flow rate of 1 ml/min.
4. Rinse the 250-ml brown glass round-bottomed flask with 10 ml of toluene/ethyl acetate (70/30, v/v) and apply the solution onto the column, too.
5. Elute the residues with 5 ml of acetonitrile at a flow rate of 1 ml/min. Collect the eluate in a 25-ml brown glass pear-shaped flask.
6. Evaporate the eluate from step 5 to dryness using a vacuum rotary evaporator and a max. bath temperature of 40 °C. Dissolve the residues in e.g. 1.00 ml of acetonitrile/water (2/8, v/v) and determine the residues with HPLC-MS/MS.

NOTE

1. **The volumes to be used for flushing the column with toluene/ethyl acetate and for elution with acetonitrile must be newly determined for each batch of silica gel.**
2. **The flow rate during loading and elution of the column should not be too high, since otherwise losses may occur leading to recoveries below 70 % and less effective clean-up.**
3. **The hydroxy-metabolite may be converted to the olefin-metabolite (especially under acidic conditions).**
4. **The olefin-metabolite is degraded by light (ca. 50% in one day at natural daylight). Therefore, all solutions containing the olefin-metabolite must be protected from light and stored in a cool and dark place.**

4.3 HPLC-MS/MS determination of Imidacloprid and Metabolites

4.3.1 Measuring equipment and HPLC conditions:

Instrument: HP 1100
 Injector: HP 1100
 Column: Phenomenex, Luna C18 (2), 5 µm, 15 cm, 0.46 cm i.d.
 or equivalent
 Injection Volume: 50 µl
 Oven temperature: 40 °C
 Mobile Phase: A: Water/ACN (90/10, v/v)+ 0.1 ml acetic acid per litre
 B: Acetonitrile + 0.1 ml acetic acid per litre

Time Table	0 min	11.1 % B
	10 min	11.1 % B
	10.1 min	90 % B
	15 min	90 % B
	15.1 min	11.1 % B
	19 min	11.1 % B

Stoptime: 19 min
 Flow (Column): 1.0 ml/min
 Flow (into MS): 0.15 ml/min
 Retention Time: Olefin-Metabolite: approx. 4.6 min
 Hydroxy-Metabolite: approx. 5.5 min
 Imidacloprid: approx. 9.1 min

NOTE: Conditions may be adapted for other HPLC-MS/MS systems.

Dit document is geen eigendom van het Ctgb en wordt beschikbaar gemaakt op grond van een wettelijke verplichting tot openbaarmaking. Op dit document kunnen rechten van derden rusten, waaronder intellectuele eigendomsrechten en/of auteursrechten. Voorts kan dit document onder een regeling omtrent gegevensbescherming vallen. De inhoud hiervan valt onder de toestemming van de rechthebbende van dit document kan anderszins beschermd zijn en een inbreuk op deze rechten van de rechthebbende.

This document is not the property of the Ctgb and is provided based on mandatory freedom of information requirements. The document may be subject to rights such as intellectual property and copy rights of third parties. Furthermore, this document may fall under a regulatory data protection regime. Publication, distribution, reproduction and any commercial exploitation and use of this document or its contents without the permission of the owner of this document may therefore be prohibited and violate the rights of its owner.

4.3.2 MS/MS-Detection

The experiments were performed on a triple-quadrupole mass spectrometer system, fitted with an electrospray interface operated in the positive ion mode under MRM conditions.

The mass spectrometer was tuned by infusing a standard solution of 0.5 mg/l imidacloprid and its metabolites (dissolved in water/acetonitrile 8/2 + 0.1 ml acetic acid per l) at a flow rate of 10-20 µl/min. Mass axis calibration was done by infusing a polypropylene glycol 3000 solution. Unit mass resolution was established and maintained in each mass resolving quadrupole by maintaining a full width at half-maximum of between 0.8 and 1.0 DA. After tuning and calibration, optimal collision-activated dissociation (CAD) conditions for fragmentation of imidacloprid and its metabolites were determined. These experiments were performed with nitrogen as collision gas with a collision offset of -19 eV for imidacloprid, -21 eV for the hydroxy-metabolite and -13 eV for the olefin-metabolite and at an approximate collision gas thickness of 1.46×10^{15} atoms/cm². Nebulizer gas is set at 1.48 l/min, curtain gas is set at 1.44 l/min, collision gas is set at 0.87 l/min and turbo gas is set at 6.0 l/min.

Detector: Triple Quadrupole LC-MS/MS Mass Spectrometer, e.g. Perkin-Elmer Sciex Instruments API 300, Apple™ Macintosh System® 8.1

Interface: Electrospray Turbo Ion Spray
 Potential: +4400 V
 Temperature: 400 °C
 Nebulizer Gas: Nitrogen 5.0 (99.999% purity), 1.48 l/min
 Curtain Gas: Nitrogen 5.0 (99.999% purity), 1.44 l/min
 Turbo Gas: Nitrogen 5.0 (99.999% purity), 6.0 l/min

Scan Type: MRM (Multiple Reaction Monitoring Mode)

Polarity: Positive

Collision Gas: Nitrogen 5.0 (99.999% purity), 0.87 l/min


Mass spectrometer operating parameters:

Compound	Precursor Ion Q1 Mass (amu)	Product Ion Q3 Mass (amu)	Dwell Time (msec)	Collision Energy (eV)
Olefin-Metabolite (37)	256 [#]	238	250	-13
Olefin-Metabolite (35)	254	236	250	-13
Hydroxy-Metabolite (37)	274 [#]	191	250	-21
Hydroxy-Metabolite (35)	272	191	250	-21
Imidacloprid (37)	258 [#]	211	500	-19
Imidacloprid (35)	256	209	500	-19

[#]: The Cl 37 isotope of all substances was detected to build the isotopes ratio

NOTE: Different MS/MS-instruments or instrument parameters may result in different ion transitions and different relative intensities.

Appendix II: Copy of the GLP Certificate



Dit document is geen eigendom
Op dit document
Publicatie, verspreiding, v
rechtthebb

Consequently, s
w

ing.
er.
or its contents

Appendix II: cont`d.



Dit document is geen eigenda
Op dit document
Publicatie, verspreiding, vermenigvuldiging
rechthebbende van dit document

This document is not the property of the
The document may be subject to
Consequently, any publication, distribution, reproduction and
without the permission of the owner of this document

making.
van de

ents.
this document or its contents
rights of its owner.

Appendix III: Quality Assurance Statement



Referat GLP
Quality Assurance Statement

Dit docum

Public

This doc
Consequently, any publicatio
without the pe

garmaking.
ng van de

its contents